Home » Long-Lasting Hemophilia Treatment Succeeds in Phase III

Long-Lasting Hemophilia Treatment Succeeds in Phase III

September 26, 2012

Partners Biogen Idec and Swedish Orphan Biovitrum reported positive data from a Phase III study evaluating the long-lasting recombinant Factor IX Fc fusion protein (rFIXFc) in hemophilia B patients.
Genetic Engineering & Biotechnology News

26Jan
Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup
27Jan
Medical Device Clinical Trials in China: Latest Regulatory Developments
27Jan
FDA’s Response to COVID-19: Fundamentals of Obtaining Emergency Use Authorizations
09Feb
Maintaining Your Risk-Based Cleaning and Disinfectant Programs: Best Practices During COVID-19
10Feb
FDA Under the Biden Administration: What’s to Come and What It Will Mean
11Feb
Lab X.0: Addressing Quality and Compliance Challenges in Laboratory Operations in the COVID-19 All-Digital Era

Long-Lasting Hemophilia Treatment Succeeds in Phase III

Upcoming Events

Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup

Medical Device Clinical Trials in China: Latest Regulatory Developments

FDA’s Response to COVID-19: Fundamentals of Obtaining Emergency Use Authorizations

Maintaining Your Risk-Based Cleaning and Disinfectant Programs: Best Practices During COVID-19

FDA Under the Biden Administration: What’s to Come and What It Will Mean

Lab X.0: Addressing Quality and Compliance Challenges in Laboratory Operations in the COVID-19 All-Digital Era

Featured Products

Biological Risk Evaluation and Management for Medical Devices

GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

Lilly’s Monoclonal Antibody Could Prevent COVID-19 in the Elderly

Fluidigm Gains CE Mark for Saliva-Based Assay for COVID-19

Regeneron’s Antibody Cocktail Shows Efficacy as COVID-19 Treatment

FDA to Review Berkshire’s 510(k) Submission for Remote Drug-Delivery System

The Revised ICH E8: A Guide to New Clinical Trial Requirements